Insmed (INSM) Analysts See $-0.76 EPS; Bokf Has Boosted By $875,442 Its General Mls (GIS) Holding

April 16, 2018 - By Peter Erickson

Insmed Incorporated (NASDAQ:INSM) Logo

Bokf increased General Mls Inc (GIS) stake by 13.61% reported in 2017Q4 SEC filing. Bokf acquired 14,838 shares as General Mls Inc (GIS)’s stock declined 24.65%. The Bokf holds 123,839 shares with $7.34 million value, up from 109,001 last quarter. General Mls Inc now has $26.74 billion valuation. The stock increased 0.67% or $0.3 during the last trading session, reaching $45.1. About 309,112 shares traded. General Mills, Inc. (NYSE:GIS) has declined 22.93% since April 16, 2017 and is downtrending. It has underperformed by 34.48% the S&P500.

Analysts expect Insmed Incorporated (NASDAQ:INSM) to report $-0.76 EPS on May, 2.They anticipate $0.16 EPS change or 26.67% from last quarter’s $-0.6 EPS. After having $-0.85 EPS previously, Insmed Incorporated’s analysts see -10.59% EPS growth. The stock decreased 1.76% or $0.41 during the last trading session, reaching $22.92. About 66,344 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 31.10% since April 16, 2017 and is uptrending. It has outperformed by 19.55% the S&P500.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.76 billion. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Among 11 analysts covering Insmed (NASDAQ:INSM), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Insmed had 27 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, January 4 by H.C. Wainwright. H.C. Wainwright maintained Insmed Incorporated (NASDAQ:INSM) rating on Monday, November 6. H.C. Wainwright has “Buy” rating and $35.0 target. Robert W. Baird maintained the shares of INSM in report on Thursday, January 4 with “Buy” rating. Robert W. Baird initiated it with “Buy” rating and $2300 target in Monday, July 10 report. The firm earned “Buy” rating on Thursday, August 3 by Cowen & Co. Stifel Nicolaus initiated it with “Buy” rating and $23 target in Tuesday, March 15 report. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Buy” rating by Cowen & Co on Thursday, July 20. The stock has “Buy” rating by Leerink Swann on Wednesday, March 14. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, September 6. The firm has “Buy” rating by Leerink Swann given on Tuesday, September 5.

Investors sentiment decreased to 1 in 2017 Q4. Its down 2.74, from 3.74 in 2017Q3. It is negative, as 27 investors sold Insmed Incorporated shares while 40 reduced holdings. 18 funds opened positions while 49 raised stakes. 73.21 million shares or 49.25% less from 144.25 million shares in 2017Q3 were reported. Victory Cap Management, a Ohio-based fund reported 598,250 shares. Vanguard Grp Incorporated owns 6.31 million shares. D E Shaw & holds 0.02% or 507,325 shares in its portfolio. Metropolitan Life Ins New York reported 24,316 shares. Proshare Llc stated it has 0.01% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Goldman Sachs accumulated 0% or 301,740 shares. Driehaus Capital Mgmt Lc reported 0.04% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Principal Financial Gp has 156,420 shares. C Worldwide Grp Inc A S holds 392,007 shares or 0.18% of its portfolio. Legal And General Grp Public Ltd Co holds 0% or 34,666 shares in its portfolio. Royal Commercial Bank Of Canada stated it has 500 shares. Rhumbline Advisers holds 0% or 74,574 shares. Emerald Advisers Pa holds 859,011 shares or 1.03% of its portfolio. Alyeska Invest Group Ltd Partnership holds 313,537 shares. California Pub Employees Retirement Systems accumulated 0% or 86,600 shares.

Investors sentiment increased to 0.89 in 2017 Q4. Its up 0.05, from 0.84 in 2017Q3. It increased, as 56 investors sold GIS shares while 388 reduced holdings. 107 funds opened positions while 288 raised stakes. 405.24 million shares or 0.97% more from 401.33 million shares in 2017Q3 were reported. Meiji Yasuda Asset Mgmt has 44,353 shares. Gofen And Glossberg Il stated it has 0.02% in General Mills, Inc. (NYSE:GIS). Boston Family Office Limited Liability reported 1.29% in General Mills, Inc. (NYSE:GIS). Riverpoint Management Ltd Com holds 352,671 shares. Rhode Island-based Richard C Young Company Limited has invested 0.47% in General Mills, Inc. (NYSE:GIS). Ruggie Cap Grp Incorporated has 0.01% invested in General Mills, Inc. (NYSE:GIS) for 179 shares. Douglass Winthrop Lc has 0.15% invested in General Mills, Inc. (NYSE:GIS). Amundi Pioneer Asset Mgmt reported 3.23 million shares stake. Pillar Pacific Cap Mgmt Limited Com holds 4,000 shares. Salem Investment Counselors Inc invested 0% of its portfolio in General Mills, Inc. (NYSE:GIS). Northstar Inv Advisors Llc invested in 1.26% or 117,695 shares. 120 are held by Management Pro. Community Bankshares Na holds 0.28% in General Mills, Inc. (NYSE:GIS) or 44,777 shares. Calamos Advisors Limited Com stated it has 67,547 shares. Ferguson Wellman accumulated 41,235 shares.

Among 24 analysts covering General Mills Inc. (NYSE:GIS), 4 have Buy rating, 3 Sell and 17 Hold. Therefore 17% are positive. General Mills Inc. had 84 analyst reports since July 21, 2015 according to SRatingsIntel. Bernstein downgraded the shares of GIS in report on Tuesday, March 21 to “Underperform” rating. The company was upgraded on Wednesday, January 3 by PiperJaffray. Goldman Sachs maintained it with “Sell” rating and $60 target in Thursday, June 30 report. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, June 17. The firm has “Outperform” rating given on Tuesday, July 21 by RBC Capital Markets. Stifel Nicolaus maintained the shares of GIS in report on Tuesday, August 8 with “Hold” rating. The stock has “Hold” rating by RBC Capital Markets on Thursday, March 22. The rating was maintained by Morgan Stanley on Friday, June 23 with “Hold”. The rating was downgraded by Stifel Nicolaus on Wednesday, March 22 to “Hold”. The company was maintained on Tuesday, May 30 by Susquehanna.

Bokf decreased Metlife Inc (NYSE:MET) stake by 8,006 shares to 45,847 valued at $2.32M in 2017Q4. It also reduced Blackrock Inc (NYSE:BLK) stake by 675 shares and now owns 18,195 shares. Hawaiian Elec Industries (NYSE:HE) was reduced too.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: